Brii Biosciences Reports Positive Phase 2 ENSURE Study Results for Hepatitis B Therapy

Reuters

11/10

Brii Biosciences Reports Positive Phase 2 ENSURE Study Results for Hepatitis B Therapy

Brii Biosciences Ltd. has announced late-breaking data from its ongoing Phase 2 ENSURE study, evaluating a novel sequential combination treatment strategy for hepatitis B virus (HBV). The 24-week post end of treatment $(EOT)$ follow-up results from Cohort 4 were presented at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, held in Washington D.C. from November 7-11, 2025, and were simultaneously published in Nature Medicine. The study assesses the use of the company's therapeutic vaccine, BRII-179, in combination with elebsiran and PEG-IFNα. Additional Phase 2b trials, including the ENRICH and ENHANCE studies, are underway, with EOT data expected to be presented in 2026. Brii Biosciences noted that the combination treatment was generally safe and well-tolerated, but cautioned there is no assurance the therapies will ultimately be successfully developed or marketed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brii Biosciences Ltd. published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2582874883"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2582874883\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2582874883?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-10 21:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582874883","market":"fut","top_or_hot":-1,"title":"Brii Biosciences Reports Positive Phase 2 ENSURE Study Results for Hepatitis B Therapy","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Brii Biosciences Reports Positive Phase 2 ENSURE Study Results for Hepatitis B Therapy\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Brii Biosciences Ltd. has announced late-breaking data from its ongoing Phase 2 ENSURE study, evaluating a novel sequential combination treatment strategy for hepatitis B virus (HBV). The 24-week post end of treatment <a href=\"https://laohu8.com/S/EOT\">$(EOT)$</a> follow-up results from Cohort 4 were presented at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, held in Washington D.C. from November 7-11, 2025, and were simultaneously published in Nature Medicine. The study assesses the use of the company's therapeutic vaccine, BRII-179, in combination with elebsiran and PEG-IFNα. Additional Phase 2b trials, including the ENRICH and ENHANCE studies, are underway, with EOT data expected to be presented in 2026. Brii Biosciences noted that the combination treatment was generally safe and well-tolerated, but cautioned there is no assurance the therapies will ultimately be successfully developed or marketed.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brii Biosciences Ltd. published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Brii Biosciences Reports Positive Phase 2 ENSURE Study Results for Hepatitis B Therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBrii Biosciences Reports Positive Phase 2 ENSURE Study Results for Hepatitis B Therapy\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-11-10 21:33</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Brii Biosciences Reports Positive Phase 2 ENSURE Study Results for Hepatitis B Therapy\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Brii Biosciences Ltd. has announced late-breaking data from its ongoing Phase 2 ENSURE study, evaluating a novel sequential combination treatment strategy for hepatitis B virus (HBV). The 24-week post end of treatment <a href=\"https://laohu8.com/S/EOT\">$(EOT)$</a> follow-up results from Cohort 4 were presented at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, held in Washington D.C. from November 7-11, 2025, and were simultaneously published in Nature Medicine. The study assesses the use of the company's therapeutic vaccine, BRII-179, in combination with elebsiran and PEG-IFNα. Additional Phase 2b trials, including the ENRICH and ENHANCE studies, are underway, with EOT data expected to be presented in 2026. Brii Biosciences noted that the combination treatment was generally safe and well-tolerated, but cautioned there is no assurance the therapies will ultimately be successfully developed or marketed.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brii Biosciences Ltd. published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDL44GStK:1","article_id":"2582874883","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582874883","pubTimestamp":1762781598,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Brii Biosciences Ltd. has announced late-breaking data from its ongoing Phase 2 ENSURE study, evaluating a novel sequential combination treatment strategy for hepatitis B virus . The 24-week post end of treatment  follow-up results from Cohort 4 were presented at the American Association for the Study of Liver Diseases  The Liver Meeting, held in Washington D.C. from November 7-11, 2025, and were simultaneously published in Nature Medicine. The study assesses the use of the company's therapeutic vaccine, BRII-179, in combination with elebsiran and PEG-IFNα. Additional Phase 2b trials, including the ENRICH and ENHANCE studies, are underway, with EOT data expected to be presented in 2026. Brii Biosciences noted that the combination treatment was generally safe and well-tolerated, but cautioned there is no assurance the therapies will ultimately be successfully developed or marketed.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","BK1587":"次新股","02137":"腾盛博药-B","BK1574":"生物医药B类股"},"translate_title":"Brii Biosciences报告乙型肝炎治疗2期确保研究结果积极","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02137":0.9},"content_text":"Brii Biosciences Reports Positive Phase 2 ENSURE Study Results for Hepatitis B Therapy\n    \n\n        Brii Biosciences Ltd. has announced late-breaking data from its ongoing Phase 2 ENSURE study, evaluating a novel sequential combination treatment strategy for hepatitis B virus (HBV). The 24-week post end of treatment $(EOT)$ follow-up results from Cohort 4 were presented at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, held in Washington D.C. from November 7-11, 2025, and were simultaneously published in Nature Medicine. The study assesses the use of the company's therapeutic vaccine, BRII-179, in combination with elebsiran and PEG-IFNα. Additional Phase 2b trials, including the ENRICH and ENHANCE studies, are underway, with EOT data expected to be presented in 2026. Brii Biosciences noted that the combination treatment was generally safe and well-tolerated, but cautioned there is no assurance the therapies will ultimately be successfully developed or marketed.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brii Biosciences Ltd. published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}